Cormorant Asset Management, an affiliate of certain officers and directors of Helix Acquisitions, loaned the SPAC $150,000 for working capital purposes, according to a regulatory filing. The non-interest bearing loan is not convertible and would not be repaid if the SPAC fails to complete a merger, except to the extent it may have funding separate from its trust.
The SPAC is in a pending merger with MoonLake Immunotherapeutics in a deal valued at $620 million. Read more.
